TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32153031

Group type: EXPERIMENTAL
Intervention: Housing First (HF) model of permanent supportive housing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scattered-site approach to HF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-site approach to HF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: University-community partnerships
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Research collaborative
Number of subjects: 0
Study: 33475743

Group type: EXPERIMENTAL
Intervention: Haploidentical related donors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unrelated umbilical cord blood (UCB)
Number of subjects: 0
Study: 34969489

Group type: EXPERIMENTAL
Intervention: Math tutoring program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33503305

Group type: EXPERIMENTAL
Intervention: Pevonedistat in combination with azacitidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Single-agent azacitidine
Number of subjects: 30
Study: 32877557

Group type: EXPERIMENTAL
Intervention: Rapid Testing (RT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Laboratory-Based Testing (LBT)
Number of subjects: 200
Study: 35298893

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 278280

Group type: EXPERIMENTAL
Intervention: Faecal immunochemical test
Number of subjects: 278280

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 278280
Study: 32067657

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combined laser therapy and chiropractic care
Number of subjects: 61

Group type: COMPARATOR
Intervention: Chiropractic treatment
Number of subjects: 61
Study: 35864163

Group type: EXPERIMENTAL
Intervention: Single-step PRK
Number of subjects: 50

Group type: COMPARATOR
Intervention: Two-step PTK-PRK
Number of subjects: 50
Study: 33189596

Group type: EXPERIMENTAL
Intervention: Running behavior (interval training, training with partner, physical distancing during training)
Number of subjects: 2586

Group type: EXPERIMENTAL
Intervention: Symptoms suggestive for COVID-19
Number of subjects: 2586

Group type: EXPERIMENTAL
Intervention: Hospital admission due to COVID-19
Number of subjects: 2586

Group type: EXPERIMENTAL
Intervention: Running behavior and running habits
Number of subjects: 2586
Study: 35916430

Group type: EXPERIMENTAL
Intervention: Standard methadone model of care
Number of subjects: 183

Group type: COMPARATOR
Intervention: Flexible buprenorphine/naloxone model of care
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Both interventions (methadone and flexible buprenorphine/naloxone)
Number of subjects: 183
Study: 32988670

Group type: EXPERIMENTAL
Intervention: CEUS-CNB
Number of subjects: 238

Group type: COMPARATOR
Intervention: US-CNB
Number of subjects: 238

Group type: COMPARATOR
Intervention: Incisional Biopsy
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: CEUS-CNB vs US-CNB
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: CEUS-CNB vs Incisional Biopsy
Number of subjects: 238
Study: 36297102

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg.kg−1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 33722384

Group type: EXPERIMENTAL
Intervention: Topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical ivermectin 1% cream and placebo
Number of subjects: 0
Study: 35476247

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32311073

Group type: EXPERIMENTAL
Intervention: Caregiver Acute Stress Paradigm (CASP) - experimental stress manipulation
Number of subjects: 106

Group type: COMPARATOR
Intervention: Non-stress manipulation
Number of subjects: 106
Study: 33829308

Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (24 IU intranasal administration)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 32008063

Group type: EXPERIMENTAL
Intervention: TPB-based intervention program (14 sessions of 1 hour during an academic year)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 185
Study: 35397638

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (160 IU/1.6 mL)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 34582460

Group type: EXPERIMENTAL
Intervention: Lay counselor-delivered, brief transdiagnostic problem-solving intervention (4 to 5 sessions over 3 weeks) with supporting printed booklets
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Lay counselor-delivered, brief transdiagnostic problem-solving intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Printed booklets alone (control arm)
Number of subjects: 250
Study: 35198175

Group type: EXPERIMENTAL
Intervention: Routine abdominal drainage
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 60
Study: 32989176

Group type: EXPERIMENTAL
Intervention: β-lactolin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 35757899

Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop (HCL) therapy using Medtronic MiniMed™ 670G system
Number of subjects: 17
Study: 32226019

Group type: EXPERIMENTAL
Intervention: Bright light therapy (10,000 lux)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Dim light placebo (500 lux)
Number of subjects: 15
Study: 34048286

Group type: EXPERIMENTAL
Intervention: MACT
Number of subjects: 48

Group type: COMPARATOR
Intervention: MFx
Number of subjects: 48
Study: 32005282

Group type: EXPERIMENTAL
Intervention: Low dose hUC-MSCs (2.5 million cells/kg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High dose hUC-MSCs (5 million cells/kg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (traditional supportive treatments alone)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 72
Study: 33064057

Group type: EXPERIMENTAL
Intervention: Interleukin (IL)‐8 group (Group 2)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard treatment group (Group 1)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 33438437

Group type: EXPERIMENTAL
Intervention: Alirocumab with achieved LDL-C <25 mg/dL
Number of subjects: 18924

Group type: EXPERIMENTAL
Intervention: Alirocumab with achieved LDL-C 25 to 50 mg/dL
Number of subjects: 18924

Group type: EXPERIMENTAL
Intervention: Alirocumab with achieved LDL-C >50 mg/dL
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study: 32728111

Group type: EXPERIMENTAL
Intervention: Combination of orthokeratology (OK) and 0.01% atropine solution
Number of subjects: 80

Group type: COMPARATOR
Intervention: Monotherapy with orthokeratology (OK)
Number of subjects: 80
Study: 33044364

Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR) intervention for 90 seconds, thrice per week over 5 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR) intervention
Number of subjects: 30
Study: 34521367

Group type: EXPERIMENTAL
Intervention: CT1 study (12,000 individuals)
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: CT2 study (urine samples from Belgian Health Examination Survey)
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Civil relationship status
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Sexual intercourse with a casual partner
Number of subjects: 12000

Group type: COMPARATOR
Intervention: > 3 sexual partners in the last 12 months
Number of subjects: 12000
Study: 32338622

Group type: EXPERIMENTAL
Intervention: IT-based intervention
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Print-based intervention
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: IT-based intervention with PA tracker (30% of IT group)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Both interventions (IT-based and print-based)
Number of subjects: 390
Study: 34313515

Group type: EXPERIMENTAL
Intervention: Virtual reality otoscopy simulator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Otolaryngologists
Number of subjects: 0
Study: 33612341

Group type: EXPERIMENTAL
Intervention: Tdap group (maternal vaccination with Tdap)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 540
Study: 32641723

Group type: EXPERIMENTAL
Intervention: Adaptive Light 1.0 (biphasic exponential dimming)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Constant light
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linear dimming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monophasic exponential dimming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biphasic exponential dimming
Number of subjects: 0
Study: 34555257

Group type: EXPERIMENTAL
Intervention: MBM intervention
Number of subjects: 290105

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 290105

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 290105
Study: 33472855

Group type: EXPERIMENTAL
Intervention: Tocilizumab (single intravenous infusion of 8 mg/kg) plus standard care (n=65)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Standard care alone (n=64)
Number of subjects: 129
Study: 32371120

Group type: EXPERIMENTAL
Intervention: Micro-training (four 15-min strength and four 15-min endurance bouts weekly)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Classical-training (one 60-min strength and one 60-min endurance training session weekly)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control-group (two 60-min standard military physical training sessions weekly)
Number of subjects: 290
Study: 35952460

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study: 32618621

Group type: EXPERIMENTAL
Intervention: Auricular acupressure intervention
Number of subjects: 68
Study: 36433884

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment (ABMT) as an add-on to regular inpatient treatment, involving two pretreatment training sessions and eight biweekly sessions.
Number of subjects: 154

Group type: COMPARATOR
Intervention: Non-ABMT intervention control condition
Number of subjects: 154
Study: 33618522

Group type: EXPERIMENTAL
Intervention: HART (preoperative hyperfractionated radiotherapy)
Number of subjects: 136

Group type: COMPARATOR
Intervention: HART-CT (concomitant hyperfractionated radiotherapy with chemotherapy)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: HART
Number of subjects: 136
Study: 33004383

Group type: EXPERIMENTAL
Intervention: Co‐PARS (coproduced PA referral scheme)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care ERS
Number of subjects: 68

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 68
Study: 34632875

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control TSST
Number of subjects: 138
Study: 34159560

Group type: EXPERIMENTAL
Intervention: Colchicine 500 mcg od
Number of subjects: 5522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5522
Study: 34432169

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 114
Study: 32359668

Group type: EXPERIMENTAL
Intervention: Interim Methadone with Patient Navigation (IM + PN)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Interim Methadone without Patient Navigation (IM)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Enhanced Treatment-as-Usual (ETAU)
Number of subjects: 212
Study: 35029292

Group type: EXPERIMENTAL
Intervention: Mefenamic acid plus standard medical care
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo plus standard medical care
Number of subjects: 36
Study: 32880057

Group type: EXPERIMENTAL
Intervention: anodal-left PFC tDCS plus placebo medication
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg/day for 3 weeks and 20 mg/day thereafter plus sham tDCS
Number of subjects: 51

Group type: COMPARATOR
Intervention: placebo medication plus sham tDCS
Number of subjects: 51
Study: 33427822

Group type: EXPERIMENTAL
Intervention: Ananya program implemented in eight intervention districts.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Comparison arm comprised of the remaining 30 districts in Bihar where Ananya interventions were not implemented.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mother's behaviours in contraceptive utilisation.
Number of subjects: 8
Study: 32243492

Group type: EXPERIMENTAL
Intervention: Inclisiran 200 mg single dose
Number of subjects: 6068

Group type: EXPERIMENTAL
Intervention: Inclisiran 300 mg single dose
Number of subjects: 6068

Group type: EXPERIMENTAL
Intervention: Inclisiran 500 mg single dose
Number of subjects: 6068

Group type: EXPERIMENTAL
Intervention: Inclisiran 100 mg double dose
Number of subjects: 6068

Group type: EXPERIMENTAL
Intervention: Inclisiran 200 mg double dose
Number of subjects: 6068

Group type: EXPERIMENTAL
Intervention: Inclisiran 300 mg double dose
Number of subjects: 6068

Group type: COMPARATOR
Intervention: Placebo single dose
Number of subjects: 6068

Group type: COMPARATOR
Intervention: Placebo double dose
Number of subjects: 6068

Group type: EXPERIMENTAL
Intervention: Inclisiran (all dosing regimens)
Number of subjects: 6068
Study: 33892624

Group type: EXPERIMENTAL
Intervention: Leisure time physical activities (LTPA)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Gardening
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Mobility training
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Impairments in activities of daily living
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Living environment
Number of subjects: 436
Study: 32928607

Group type: EXPERIMENTAL
Intervention: BISCPM (Brain Injury State Clinical Prediction Model)
Number of subjects: 1156

Group type: EXPERIMENTAL
Intervention: BISCPM
Number of subjects: 1156
Study: 32772618

Group type: EXPERIMENTAL
Intervention: h-COR test
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: n-COR test
Number of subjects: 39

Group type: COMPARATOR
Intervention: Group B (without oscillopsia)
Number of subjects: 39
Study: 35304647

Group type: EXPERIMENTAL
Intervention: Targeted tidal volume of 4 ml/kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Targeted tidal volume of 5 ml/kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Targeted tidal volume of 6 ml/kg
Number of subjects: 9
Study: 32960408

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus panitumumab (Pani)
Number of subjects: 101

Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab (Bev)
Number of subjects: 101
Study: 34286472

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (cholecalciferol 100,000 UI per 10 days over 1 month)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low-dose vitamin D (ergocalciferol 400 UI/days over 1 month)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low-dose vitamin D
Number of subjects: 31
Study: 33581798

Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA-617
Number of subjects: 200

Group type: COMPARATOR
Intervention: cabazitaxel
Number of subjects: 200
Study: 34517768

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 0
Study: 32380119

Group type: EXPERIMENTAL
Intervention: Carbon-Heated Tobacco Product (CHTP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cigarettes
Number of subjects: 120
Study: 33722330

Group type: EXPERIMENTAL
Intervention: Starter feed supplemented with 3% soyabean oil (SBO)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Starter feed supplemented with 3% fish oil (FO)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Equal mixture of SBO and FO (1.5% each, DM basis)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Starter feed with no fat source (CON)
Number of subjects: 40
Study: 33830960

Group type: EXPERIMENTAL
Intervention: Extended intervals despite residual subretinal fluid (rSRF)
Number of subjects: 98
Study: 33371148

Group type: EXPERIMENTAL
Intervention: Active NAE therapy (n=20)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham stimulation (n=17)
Number of subjects: 37
Study: 35714891

Group type: EXPERIMENTAL
Intervention: Vascular Quality of Life Questionnaire (VascQOL)
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: European Quality of Life 5D (EQ-5D)
Number of subjects: 1830

Group type: EXPERIMENTAL
Intervention: Short Form 12 (SF-12)
Number of subjects: 1830
Study: 34979631

Group type: EXPERIMENTAL
Intervention: Combination of 0.3 mg/kg IV ketamine and 40.0 mg IV parecoxib (group K-P)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0.3 mg/kg IV ketamine alone (group K)
Number of subjects: 48
Study: 35580635

Group type: EXPERIMENTAL
Intervention: Oxygen (10 L per minute by simple, tight‐fitting face mask until delivery)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Room air (without a face mask)
Number of subjects: 140
Study: 32826635

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Resistance Training with Blood Flow Restriction (RT + BFR)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Monocyte Chemoattractant Protein 1
Number of subjects: 105
Study: 37659086

Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 360

Group type: COMPARATOR
Intervention: Active control (self-help manual)
Number of subjects: 360
Study: 33609057

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil injection (test product)
Number of subjects: 24

Group type: COMPARATOR
Intervention: ROPION (reference drug)
Number of subjects: 24
Study: 32553489

Group type: EXPERIMENTAL
Intervention: Enhanced bathing and decolonization
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 1400
Study: 35109780

Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 32032804

Group type: EXPERIMENTAL
Intervention: Passive gesture intervention (watching movies with intensive use of gesture)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Active gesture intervention (Visual Action Therapy)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 3
Study: 35063214

Group type: EXPERIMENTAL
Intervention: Vitamin D supplement (1000 IU + 25 g canola oil daily, n=31)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Vitamin D fortified oil (placebo tablet + 25 g canola oil fortified with 1000 IU vitamin D daily, n=30)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (placebo tablet + 25 g canola oil, n=32)
Number of subjects: 93
Study: 34175968

Group type: EXPERIMENTAL
Intervention: Epinephrine in normal saline (1:100,000)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 50
Study: 34882076

Group type: EXPERIMENTAL
Intervention: Indapamide retard 1.5 mg and valsartan 160 mg in the morning (Group 1)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Indapamide retard 1.5 mg in the morning and valsartan 160 mg in the evening (Group 2)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Indapamide retard 1.5 mg in the morning and valsartan 80 mg in the morning and evening (Group 3)
Number of subjects: 174
Study: 33853650

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS) performed by a credentialled practitioner
Number of subjects: 112

Group type: COMPARATOR
Intervention: X-ray imaging
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 112
Study: 35459688

Group type: EXPERIMENTAL
Intervention: Mindfulness-based supportive therapy (MBST)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 33971616

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Physiotherapist insights
Number of subjects: 13
Study: 32750921

Group type: EXPERIMENTAL
Intervention: Blockchain-enabled contextual online learning model under local differential privacy
Number of subjects: 0
Study: 33107050

Group type: EXPERIMENTAL
Intervention: Common treatment area (owner absent)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Isolated exam room (owner present)
Number of subjects: 44
Study: 35341011

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Common postoperative treatment
Number of subjects: 50
Study: 33856748

Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA (ctDNA) screening tests such as CancerSEEK or GRAIL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA (ctDNA) screening tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 0
Study: 32619240

Group type: EXPERIMENTAL
Intervention: 8-h split sleep
Number of subjects: 111

Group type: COMPARATOR
Intervention: 8-h continuous sleep
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 6.5-h split sleep
Number of subjects: 111

Group type: COMPARATOR
Intervention: 6.5-h continuous sleep
Number of subjects: 111
Study: 35607710

Group type: EXPERIMENTAL
Intervention: Isoniazid prophylaxis at 6 weeks of age
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 34310883

Group type: EXPERIMENTAL
Intervention: Non-linear periodisation (NLP)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Linear periodisation (LP)
Number of subjects: 30
Study: 32427934

Group type: EXPERIMENTAL
Intervention: Vertical current steering (vCS)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Single-contact stimulation
Number of subjects: 7
Study: 36079725

Group type: EXPERIMENTAL
Intervention: Barley consumption for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control food for 4 weeks
Number of subjects: 0
Study: 33168398

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (AC)
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Nephroureterectomy (NU) alone
Number of subjects: 100000